$ cat ./records/gates-foundation-commits-100-million-to-curevac-for-mrna-vaccine--2015.txt
Gates Foundation Commits $100 Million to CureVac for mRNA Vaccine Development
[RECORD.TXT] · cat --full
The Bill & Melinda Gates Foundation announced a $52 million equity investment in CureVac — a German biopharmaceutical company specializing in messenger RNA technology — plus $48 million in grant funding for specific vaccine development projects, totalling $100 million. The equity supported construction of a new GMP manufacturing facility. Initial vaccine programs targeted rotavirus and HIV, diseases disproportionately affecting populations in low-income countries. This was one of the earliest large institutional commitments to mRNA as a vaccine platform by any major philanthropic organization.
Source: https://www.gatesfoundation.org/ideas/media-center/press-releases/2015/03/curevac-collaboration
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Delivers TED Talk 'The Next Outbreak? We're Not Ready' Warning of Pandemic Risk
Next →
Launches Breakthrough Energy Coalition with 27 Investors at COP21
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.